Kromek announces that it has been awarded funding from the UK’s Innovation agency, Innovate UK, for a three-year programme to deliver, in partnership with one of the country’s few ‘Outstanding’ NHS Trusts, Newcastle-upon-Tyne Hospitals NHS Foundation Trust (Newcastle Hospitals), a Low Dose Molecular Breast Imaging (LDMBI) technology based on Kromek’s CZT-based SPECT detectors. The project, commencing in mid-2018, is worth £1.4m.
Dr Arnab Basu, CEO of Kromek, said: “This project is further evidence that CZT-based detectors are becoming a core technology in replacing legacy diagnostic products across the medical imaging sector. Our innovative SPECT detectors are capable of significantly lowering radiation doses, thereby offering cost savings for health service and, crucially, makes enhanced detection and early diagnosis of breast cancer accessible on a much wider scale. We look forward to collaborating with Newcastle-upon-Tyne Hospitals NHS Foundation Trust as well as our OEM partner to carry out this vital work.”